Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Argus Health
Queensland Health
Colorcon
McKesson
Julphar
Novartis
Citi
Dow
Moodys

Generated: October 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,932,547

« Back to Dashboard

Which drugs does patent 5,932,547 protect, and when does it expire?


Patent 5,932,547 protects VIADUR and is included in one NDA.

This patent has forty-eight patent family members in twenty-nine countries.

Summary for Patent: 5,932,547

Title: Non-aqueous polar aprotic peptide formulations
Abstract:This invention relates to stable non-aqueous polar aprotic formulations of peptide compounds. These stable formulations comprise peptide in non- aqueous polar aprotic solvent. They may be stored at elevated temperatures for long periods of time and are especially useful in implantable delivery devices for long term delivery of drug.
Inventor(s): Stevenson; Cynthia L. (Mountain View, CA), Prestrelski; Steven J. (Mountain View, CA)
Assignee: ALZA Corporation (Palo Alto, CA)
Application Number:08/874,233
Patent Claim Types:
see list of patent claims
Formulation; Compound; Delivery; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Ortho Mcneil Janssen
VIADUR
leuprolide acetate
IMPLANT;IMPLANTATION021088-001Mar 3, 2000DISCNNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 5,932,547

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,124,261 Non-aqueous polar aprotic peptide formulations► Subscribe
6,235,712 Non-aqueous polar aprotic peptide formulations► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,932,547

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina007714► Subscribe
Austria224199► Subscribe
Austria263570► Subscribe
Australia3587997► Subscribe
Australia739169► Subscribe
Australia775395► Subscribe
Australia9729501► Subscribe
Brazil9710132► Subscribe
Canada2259557► Subscribe
China101116742► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Baxter
Novartis
Johnson and Johnson
Colorcon
Mallinckrodt
US Army
Harvard Business School
Boehringer Ingelheim
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot